Treatment resistant depression?treatment resistant schizophrenia
Conditions
Interventions
TRD group 1:ECT
TRD group 2 :MST
TRS group 1 :MST
TRS group 2:MECT
TRS group 3 :Oral medication
TRS Healthy control group:nothing
Sponsors
The First Affiliated Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria of patients with refractory depression were as follows 1. Patients who met the DSM-V criteria for major depression; 2. Patients with HAMD-17 score > 17; 3. For patients who meet the diagnostic criteria of TRD, TRD is defined as patients who have previously used two or more different kinds of antidepressant drugs in sufficient amount and for a full course ( >= 6 weeks) of treatment failure; 4. Patients aged 18-60 years old; 5. Patients with normal laboratory examination (routine blood test, biochemical test) and ECG examination; 6. Obtain the written informed consent of the patient or his guardian or legal representative. The inclusion criteria of refractory schizophrenia were as follows 1. Patients aged 18-50 years old; 2. Patients with schizophrenia diagnosed by dsm-5; 3. Screening the patients with positive and negative symptom scale (PANSS) score >= 60 at visit and baseline visit; 4. The patients treated with two antipsychotic drugs with different chemical structures in sufficient dose and full-term treatment (daily dose >= 600 mg chlorpromazine or equivalent dose, treatment dose lasting for more than 6 weeks) failed to achieve clinical remission; 5. Patients who sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with any mental illness except depression and schizophrenia diagnosed by DSM-V axis I; 2. Patients with abnormal ECG or laboratory results may affect the efficacy and safety evaluation; 3. Patients with severe heart, liver, kidney, eye, nervous system, endocrine system and blood system diseases that may interfere with the study or increase the risk of patients participating in the study were excluded; 4. Patients with substance dependence and abuse within 6 months; 5. Patients taking valproate (benzodiazepine hypnotics are allowed); 6. Patients who received ECT or MST treatment within 6 months before enrollment; 7. Pregnant, lactating or planned pregnancy patients; 8. Patients with intracranial metal objects and / or pacemaker carriers to prevent potential adverse effects of TMS. 9. Patients who can't take the medicine according to the doctor's advice or have no guardian. 10. Patients who have participated in other clinical trials within 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TEP;GAMF;CEA;cognitive function;miRNA;circRNA;mRNA;MRI;fMRI;DTI; | — |
Countries
China
Contacts
Public ContactSha Liu
The First Affiliated Hospital of Shanxi Medical University
Outcome results
None listed